Additionally, two studies in Sweden and Scotland suggested that women using insulin glargine alone had a significantly higher risk of breast cancer as compared with users of other types of insulin, whereas this increased risk was not observed among those who received insulin glargine in combination with other insulin [8], [9]. The gene discussed is INS; the disease is breast carcinoma.